Snapshot from Sep 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Business earnings release

Junshi Biosciences 2026 Interim Results

Analysis based on 8 articles · First reported Aug 26, 2026 · Last updated Aug 27, 2026

Sentiment
60
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The strong revenue growth and return to profitability are likely to boost investor confidence in Junshi Biosciences, potentially supporting its stock price on both the Hong Kong and Shanghai exchanges. The licensing deal with Fosun Pharmaceutical Group and international approvals for toripalimab expand the company's commercial potential and may positively impact its valuation.

Biopharmaceuticals Pharmaceuticals

Shanghai Junshi Biosciences Co., Ltd announced its 2026 interim financial results and corporate updates. Total revenue for H1 2026 reached approximately RMB1,696 million, a 45% increase year-over-year, driven by strong sales of toripalimab (domestic sales RMB1,299 million, up 36%) and increased out-licensing revenue. The company turned profitable with profit attributable to owners of RMB26 million (RMB153 million excluding share-based payment). R&D expenses were RMB644 million. The company issued technology innovation bonds generating RMB1,000 million net cash inflow, and total cash and financial products reached RMB3,670 million. Pipeline advancements include multiple regulatory approvals for toripalimab in various countries (Oman, Qatar, Singapore, Malaysia, South Africa, Peru, Brazil), NDA acceptance for JS001sc, sNDA approval for TUOYI in combination with disitamab vedotin for urothelial carcinoma, and positive phase 3 results in NSCLC. External collaborations include a licensing agreement with Fosun International — Fosun Wanbang Pharma Group for roconkibart (upfront RMB215 million, milestones up to RMB1,125 million) and a dengue vaccine license from the China — Chinese Academy of Sciences. Chairman Dong Junfeng increased his shareholding by 0.32%.

stock
Core entity; reported strong H1 2026 results with 45% revenue growth and profitability, advanced pipeline, and secured licensing deals.
Importance 100.0 Sentiment 80.0
govactor
Regulatory body that accepted NDA for JS001sc and approved sNDA for TUOYI combination; approvals support Junshi's pipeline.
Importance 20.0 Sentiment 0.0
stock
Parent of Fosun International — Fosun Wanbang Pharma Group; licensing agreement for roconkibart provides Junshi with upfront and milestone payments.
Importance 20.0 Sentiment 0.0
subs
Licensed rights to develop and commercialize roconkibart in Greater China; pays upfront and milestones to Junshi.
Importance 20.0 Sentiment 0.0
govactor
Licensed dengue vaccine rights to JunTop Biosciences, a subsidiary of Junshi, expanding its vaccine portfolio.
Importance 15.0 Sentiment 0.0
cnt
Home market for Junshi; domestic sales of toripalimab grew 36%.
Importance 10.0 Sentiment 0.0
exch
Listing venue for Junshi Biosciences; results may influence trading activity.
Importance 10.0 Sentiment 0.0
exch
Listing venue for Junshi Biosciences; results may influence trading activity.
Importance 10.0 Sentiment 0.0
per
Chairman and controlling shareholder; increased shareholding, signaling confidence.
Importance 10.0 Sentiment 0.0
cnt
Market where toripalimab is approved; part of international expansion.
Importance 5.0 Sentiment 0.0
cnt
Approved toripalimab indications, expanding market access.
Importance 5.0 Sentiment 0.0
cnt
Approved toripalimab indications, expanding market access.
Importance 5.0 Sentiment 0.0
cnt
Approved toripalimab indications, expanding market access.
Importance 5.0 Sentiment 0.0
cnt
Approved toripalimab indications, expanding market access.
Importance 5.0 Sentiment 0.0
curr
Reporting currency; no direct impact.
Importance 5.0 Sentiment 0.0
+ 4 more entities View on Dashboard
China related ↔ Dong Junfeng
China strategic rivals ↔ United States China views the United States as a strategic rival, characterized by ongoing trade disputes, technological competition,
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.